Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Article in English | MEDLINE | ID: mdl-22223595

ABSTRACT

Most studies employing electronic bottle monitors to measure antiretroviral adherence are limited to 24 weeks of duration, providing a snapshot of adherence from a treatment course that may be lifelong. The stability of these measures in individual patients over time has not been previously described. We measured antiretroviral adherence using Medication Event Monitoring System (MEMS) caps in a patient cohort in 2004 and 2005 and repeated the measurement in 2008 and 2009. Forty-eight participants completed both monitoring periods. Mean adherence rates in the first and second periods were 74.2% and 68.9%, respectively. Adherence rates from the 2 periods for individual participants were highly correlated (Spearman rho = .66, P < .001).


Subject(s)
Anti-HIV Agents/therapeutic use , Drug Packaging , HIV Infections/drug therapy , Medication Adherence , Adult , Antiretroviral Therapy, Highly Active , Electronics , Female , HIV Infections/virology , Humans , Male , Middle Aged , Viral Load
2.
Article in English | MEDLINE | ID: mdl-22544446

ABSTRACT

BACKGROUND: Antiretroviral therapy is associated with adverse events (AEs). The most frequently reported AE associated with lopinavir/ritonavir (LPV/r) containing regimens is diarrhea. The objective of this meta-analysis is to describe the incidence, prevalence, and duration of diarrhea in individuals taking LPV/r. METHODS: This is a meta-analysis of Abbott-conducted clinical trials. Inclusion criteria included prospective randomized clinical trials with the LPV/r tablet formulation and had AE data (moderate/severe diarrhea) available through 48 weeks of treatment. RESULTS: Three trials (total 1469 participants) met the inclusion criteria. In all, 11.2% of participants reported moderate/severe diarrhea by week 8, with median time to resolution of 7.4 weeks. The overall 48-week incidence of moderate/severe diarrhea was 15.5%. The discontinuation rate due to moderate/severe diarrhea was 1.3%. CONCLUSIONS: Moderate/severe diarrhea occurred in less than 1 in 6 participants taking LPV/r, typically started in the first 8 weeks of treatment and infrequently resulted in premature discontinuation.


Subject(s)
Anti-HIV Agents/adverse effects , Diarrhea/chemically induced , Diarrhea/epidemiology , HIV Infections/drug therapy , HIV-1 , Lopinavir/adverse effects , Ritonavir/adverse effects , Antidiarrheals/therapeutic use , Diarrhea/drug therapy , Drug Combinations , Drug Therapy, Combination , HIV Infections/virology , Humans , Incidence , Prevalence , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL